Skip to content

Research at St Andrews

Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

Research output: Contribution to specialist publicationArticle

DOI

Abstract

There is an increasing flow of new antituberculosis chemical entities entering the tuberculosis drug development pipeline. Although this is encouraging, the current number of compounds is too low to meet the demanding criteria required for registration, shorten treatment duration, treat drug-resistant infection, and address pediatric tuberculosis cases. More new chemical entities are needed urgently to supplement the pipeline and ensure that more drugs and regimens enter clinical practice. Most drug discovery projects under way exploit enzyme systems deemed essential in a specific Mycobacterium tuberculosis biosynthetic pathway or develop chemical scaffolds identified by phenotypic screening of compound libraries, specific pharmacophores or chemical clusters, and natural products. Because the development of a compound for treating tuberculosis is even longer than for treating other infection indications, the identification of selective, potent, and safe chemical entities early in the drug development process is essential to ensure that the pipeline is filled with new candidates that have the best chance to reach the clinic.
Close

Details

Original languageEnglish
PagesS1-7
Number of pages8
Volumesupplement
Specialist PublicationJournal of Infectious Diseases
PublisherInfectious Diseases Society America
DOIs
Publication statusPublished - Mar 2012

    Research areas

  • tuberculosis, MEDICINAL CHEMISTRY

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy.

    Research output: Contribution to journalArticle

  2. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  3. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

  4. Molecular bacterial load assay (MBLA) concurs with culture on the NaOH-induced Mycobacterium tuberculosis loss of viability

    Mtafya, B., Sabiiti, W., Sabi, I., John, J., Sichone, E., Ntinginya, N. E. & Gillespie, S. H., 25 Jun 2019, In : Journal of Clinical Microbiology. 57, e01992-18.

    Research output: Contribution to journalArticle

  5. Heat-inactivation renders sputum safe and preserves Mycobacterium tuberculosis RNA for downstream molecular tests

    Sabiiti, W., Azam, K., Esmeraldo, E., Bhatt, N., Rachow, A. & Gillespie, S. H., Mar 2019, In : Journal of Clinical Microbiology. 57, 4, 8 p., e01778-18.

    Research output: Contribution to journalArticle

Related by journal

  1. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations

    Svensson, R. J., Svensson, E. M., Aarnoutse, R. E., Diacon, A. H., Dawson, R., Gillespie, S. H., Moodley, M., Boeree, M. J. & Simonsson, U. S. H., 28 Apr 2018, In : Journal of Infectious Diseases. In press

    Research output: Contribution to journalArticle

  2. Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

    Phillips, P. P. J., Gillespie, S. H., Boeree, M., Heinrich, N., Aarnoutse, R., McHugh, T., Pletschette, M., Lienhardt, C., Hafner, R., Mgone, C., Zumla, A., Nunn, A. J. & Hoelscher, M., 15 May 2012, In : Journal of Infectious Diseases. 205, p. S250-S257 8 p.

    Research output: Contribution to journalArticle

  3. Fragmented population structure of Plasmodium falciparum in a region of declining endemicity

    Anthony, T. G., Conway, D. J., Cox-Singh, J., Matusop, A., Ratnam, S., Shamsul, S., Singh, B. & Cox Singh, J., 1 May 2005, In : Journal of Infectious Diseases. 191, 9, p. 1558-1564 7 p.

    Research output: Contribution to journalArticle

  4. Iron Regulates Hepatitis C Virus Translation via Stimulation of Expression of Translation Initiation Factor 3

    Theural, I., Zoller, H., Obrist, P., Datz, C., Bachmann, F., Elliott, R. M. & Weiss, G., 15 Aug 2004, In : Journal of Infectious Diseases. 190, 4, p. 819-825 7 p.

    Research output: Contribution to journalArticle

ID: 19426387